Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Remedy Entertainment Plc: Managers' Transactions ­– Sami Järvi

Remedy Entertainment Plc     Stock Exchange Release     January 3, 2024 at 2:00 p.m. (EET)  Managers' Transactions ­– Sami Järvi Person subject to the notification requirement Name: Sami Järvi Position: Other senior manager Issuer: Remedy Entertainment Oyj LEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATION Reference number: 48455/6/6 ____________________________________________ Transaction date: 2024-01-03 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: Remedy

Remedy Entertainment Plc: Managers' Transactions ­– Terhi Kauppi

Remedy Entertainment Plc     Stock Exchange Release     January 3, 2024 at 2:00 p.m. (EET)  Managers' Transactions ­– Terhi Kauppi Person subject to the notification requirement Name: Terhi Kauppi Position: Chief Financial Officer Issuer: Remedy Entertainment Oyj LEI: 7437003VZ3JPF7DBTG92 Notification type: INITIAL NOTIFICATION Reference number: 48446/6/6 ____________________________________________ Transaction date: 2024-01-03 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument:

General, Corporate and Website Update

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS AMENDED. ON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Oscillate Plc AQSE: MUSH (“Oscillate” or the “Company”) GENERAL, CORPORATE AND WEBSITE UPDATE The Company is pleased to provide a corporate update. With Steve Xerri’s appointment as Executive Director approximately 7 weeks ago, the Board has

Quarterly Disclosure

SVM UK Emerging Fund PlcQuarterly Disclosure – 03 January 2024  In accordance with UKLA Listing Rule 15.6.8, requiring UK listed investmentcompanies to notify, within five business days of the end of each quarter, alist of all investments in other investment companies that do not have astated investment policy to invest no more than 15% of their gross assets inother UK-listed investment companies (including investment trusts), SVM UKEmerging Fund Plc announces that, as at 29 December 2023, it had noinvestments in such other investment companies.    For further

Risk model based on routine blood work predicts treatment response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

A risk model developed by researchers can help to identify cancer patients who could benefit from immune checkpoint inhibitors, ICIs. Published in BMC Cancer, the study was conducted at the University of Eastern Finland and Kuopio University Hospital. Immune checkpoint inhibitors are used to treat a variety of different cancers. ICIs are antibodies that sensitise the body’s own immune system to detect and destroy tumours. However, ICIs are not effective in all patients, and systemic cancer-related inflammation, for example, may influence the efficacy of ICIs. In the new study, six

SmartCella strengthens team by recruiting Dr. Nina Bauer as Chief Business Officer

SmartCella Holding AB today announces that Dr. Nina Bauer, MBA, has been appointed Chief Business Officer and Head of Smartwise. Nina Bauer joins in January 2024 from MilliporeSigma, where she most recently held the role of Global Head of Commercial, Viral Vector and Biologics CDMO. She will be a member of the SmartCella Exceutive Management Team, and based in Boston (MA, USA).SmartCella is an innovative biotech and medtech company that combines the development of future stem cell and RNA-based therapies and methods for administering such treatments via targeted delivery into organs and

Wetteri Plc – Managers' Transactions – PM Ruukki Oy

Wetteri Plc   Manager’s Transactions   3 January 2024 12.00 EETWetteri Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: PM Ruukki Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Markku Kankaala Position: Member of the Board Issuer: Wetteri Oyj LEI: 743700TDB62DGAFROB24 Notification type: INITIAL NOTIFICATION Reference number: 48461/5/4 ____________________________________________ Transaction date:

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B0BDCB21 Issuer Name STRATEGIC EQUITY CAPITAL PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name 1607 Capital Partners, LLC City of registered office (if applicable) Richmond Country of registered office (if applicable) United States 4. Details of the shareholder +-------------+-------------------------+----------------------------+|Name

Invitation to the Tokmanni Group’s Capital Markets Day 2024

Tokmanni Group Corporation        Investor news        3 January 2024 at 11:45 amThe Tokmanni Group is pleased to invite investors, analysts and other capital market and media representatives to its Capital Markets Day on Tuesday 13 February 2024 from 1 pm to 3 pm Finnish time. The event will be held at Tokmanni’s new Moreeni logistics centre in Mäntsälä. At the event, the Group’s management will present information on the company’s updated strategy and other topical issues. The event will also be streamed live via a webcast, which can be viewed by anyone, at https://ir.tokmanni.fi/en/

Konecranes Plc - Managers' transactions - Anders Svensson

Konecranes Plc - Managers' transactions - Anders Svensson____________________________________________ Person subject to the notification requirementName: Svensson, AndersPosition: Chief Executive OfficerIssuer: Konecranes PlcLEI: 549300EF0CDEQZBMA096 Notification type: INITIAL NOTIFICATIONReference number: 549300EF0CDEQZBMA096_20240103092224_380____________________________________________ Transaction date: 2024-01-02Venue not applicableInstrument type: SHAREISIN: FI0009005870Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(

WindowMaster International A/S to deliver products for the retrofit of US medical building

Investor News No. 020 - 2024WindowMaster has won a contract involving the retrofit of a government medical insurance administrative building in San Jose, California. The order includes a motorized window/vent control solution for 168 units of high-to-reach windows. In addition to the natural ventilation solution, WindowMaster will contribute to future occupant safety by delivering smoke and heat exhaust solutions for 64 roof vents. General info about Investor News: Unless otherwise stated, all new customer agreements and orders are according to WindowMaster’s strategy

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 3 - 3 JANUARY 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 2 - 3 JANUARY 2024   On 2 November 2023, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 2 November 2023 up to and including no later than 31 January 2024. For details, please see announcement no. 186 of 2 November 2023.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 30 million (approximately DKK 210

Notice of Extraordinary General Meeting in Bonava AB (publ)

The shareholders of Bonava AB (publ), reg. no. 556928-0380, ("Bonava") are hereby invited to an Extraordinary General Meeting to be held on Wednesday 7 February 2024 at 14:00 (CET), at Advokatfirman Cederquist's premises, Hovslagargatan 3 in Stockholm, Sweden. Registration for the Extraordinary General Meeting will commence at 13:30 (CET). Participation Shareholders who wish to participate in the Extraordinary General Meeting shall: · be listed in the shareholders' register maintained by Euroclear Sweden AB on Tuesday 30 January 2024,   · give notice to the company of

Receives provisional patent protection for prediction of nerve damage caused by chemotherapy

The company's patent application "CIPN Prediction ", to assess the risk of developing permanent nerve damage when treating cancer with chemotherapy, is published by the European Patent Office EPO on January 3, 2024. With the publication of the application, the company has a "provisional protection" for patent infringement.The patent application "CIPN Prediction” describes a method and a Biomarker to assess the risk, in different treatment options, to develop permanent nerve damage after completion of treatment. With the patent as a basis, the company's preliminary algorithm can provide

Change of Registered Office

3 January 2024   Quantum Blockchain Technologies Plc (“the Company”)     Change of Registered Office Address   The board of Quantum Blockchain Technologies (AIM: QBT) announces that the Registered Office address of the Company has changed to First Floor, 1 Chancery Lane, London, England, WC2A 1LF with immediate effect.       For further information please contact:   Quantum Blockchain Technologies PlcFrancesco Gardin, CEO and Executive Chairman +39 335 296573   SP Angel Corporate Finance (Nominated Adviser & Broker)Jeff Keating +44 (0)20

Pre Stabilisation Announcement - Allianz EUR 30.5NC10.5

Pre-Stabilisation Notice   January 03, 2024   Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.     Allianz SE EUR 30.5NC10.5 Subordinated Tier 2 Fixed to Floating Rate Notes with scheduled maturity in 2054 Launched pursuant to the Issuer’s Debt Issuance Programme with a separate Terms and Conditions document     Commerzbank AG (contact: Ian Turner; telephone: +44-207-7475-1817) hereby announces, as Stabilisation Coordinator, that the Stabilising Managers named

Invitation to Epiroc’s results presentation for Q4 2023 on January 24

Stockholm, Sweden: Epiroc AB, a leading productivity and sustainability partner for the mining and infrastructure industries, will publish its Q4 2023 results on Wednesday January 24 at approximately 11.30 CET. A results presentation for investors, analysts and media will be held at 14.00 CET.The report will be presented by President and CEO Helena Hedblom and CFO Håkan Folin. It will be held in English and begin with a short presentation of the report followed by a question-and-answer session. To follow the presentation webcast, either access the link here 

Metso awarded a 5-year Life Cycle Services agreement in North America

Metso Corporation’s press release on January 3, 2024, at 10:00 a.m. EETMetso has signed a 5-year Life Cycle Services (LCS) agreement with a major mining company in North America. The agreement includes several key equipment technologies supporting the needs of the customer’s various sites. Through collaborative planning between Metso and the customer, the agreement will enable consistency, transparency, and ease of doing business. The contract is one of the largest LCS orders received by Metso. The order, spanning a 5-year period, is of significant value, with the first part of the order

Iconic Love Boat returning to Helsinki – many remember Viking Cinderella for its top artists, mega weddings and TV shows

Although Viking Cinderella has not been to Finland in nearly 20 years, it is still  many people's favourite vessel. A number of cultural phenomena back in those days were born on Cinderella: the vessel is remembered for its hot artists, most popular TV shows and GOOM cruises. At the turn of the millennium, 70 couples were married on board the vessel the same day – no wonder Cinderella's biggest fans call it the Love Boat.When Cinderella sailed its maiden voyage from Helsinki to Stockholm in 1989, the vessel was not just the biggest car ferry on the Baltic Sea but also its most luxurious.

Atlas Copco Group has complemented industrial pumps portfolio with external gear pumps manufacturer

Nacka, Sweden, January 03, 2024: KRACHT GmbH (Kracht), a manufacturer of high-quality technologies including external gear pumps, fluid measurement, valves, hydraulic drives, and dosing systems has become part of Atlas Copco Group.Kracht was founded in 1911 and has its headquarters in Werdhol, Germany. The company has subsidiaries in US, China and Hungary, and approximately 440 employees. In 2022, Kracht had revenues of approximately 72 MEUR (766 MSEK*). The purchase price is not disclosed. The acquisition was announced December 4[th] 2023 and is now closed. The business has become part

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 3, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 2, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |88,162 |4.3517

Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Faron Pharmaceuticals Oy(“Faron” or “Company”)   Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference   Press release   TURKU, FINLAND / BOSTON, MA – January 3, 2024 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate immunity in hematological and solid tumor microenvironments, today announces that Dr. Markku Jalkanen, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday

There are no items matching the current filter
There are no more items matching the current filter
Back to top